New EU regulation on health technology assessment of cancer medicines
- 31 January 2022
- journal article
- letter
- Published by Elsevier in The Lancet Oncology
- Vol. 23 (2) , e58-E58
Abstract
No abstract availableFunding Information
- Swiss National Science Foundation
- Cancer Research Foundation Switzerland
This publication has 3 references indexed in Scilit:
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysisThe Lancet Oncology, 2020
- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit ScoreJournal of Clinical Oncology, 2019
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017